NovoCure (NASDAQ:NVCR) Shares Gap Down – Should You Sell?

NovoCure Limited (NASDAQ:NVCR)’s share price gapped down prior to trading on Thursday . The stock had previously closed at $14.99, but opened at $13.25. NovoCure shares last traded at $12.0820, with a volume of 712,309 shares trading hands.

NovoCure News Roundup

Here are the key news stories impacting NovoCure this week:

• Positive Sentiment: Q4 results beat EPS expectations (loss of $0.22 vs. est. -$0.41) and revenue was essentially in line, with revenue up ~8% year‑over‑year — evidence of top‑line momentum as the company scales. Article Title
• Positive Sentiment: Management raised FY‑2026 revenue guidance to $675M–$705M, above consensus (~$670M), which supports revenue growth expectations for the year ahead. Article Title
• Positive Sentiment: HC Wainwright increased its price target (to $49) and maintained a Buy rating — a bullish analyst call that could support investor interest given the large implied upside vs. current levels. Article Title
• Neutral Sentiment: Analyst coverage is mixed but active — a recent Benzinga deep dive summarizes four analyst viewpoints, useful for gauging near‑term sentiment and differential expectations. Article Title
• Neutral Sentiment: The full earnings call transcript and slide deck are available — management discussed strategic growth initiatives (market expansion and commercial execution), which investors should review for details on cadence and investments. Article Title
• Negative Sentiment: Despite revenue growth and beats, NovoCure remains loss‑making with a negative net margin (~27.7%) and negative ROE; analysts still model a negative EPS for the year, keeping valuation and profitability concerns front‑of‑mind. Article Title
• Negative Sentiment: Management flagged operational challenges on the call (execution and other near‑term issues), which could constrain margin improvement and near‑term cash flow conversion. Article Title

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on the company. HC Wainwright upped their price target on NovoCure from $47.00 to $49.00 and gave the company a “buy” rating in a research report on Thursday. Weiss Ratings reissued a “sell (e+)” rating on shares of NovoCure in a report on Thursday, January 22nd. Wedbush reaffirmed a “neutral” rating and issued a $18.00 price target on shares of NovoCure in a report on Thursday, January 15th. Finally, Evercore set a $20.00 price objective on shares of NovoCure in a research note on Monday, January 5th. Three research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $26.93.

NovoCure Trading Down 0.6%

The firm’s fifty day moving average price is $12.73 and its 200-day moving average price is $12.65. The company has a market cap of $1.53 billion, a price-to-earnings ratio of -11.20 and a beta of 0.73. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.55 and a quick ratio of 1.50.

NovoCure (NASDAQ:NVCR) last released its quarterly earnings data on Thursday, February 26th. The medical equipment provider reported ($0.22) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.19. The business had revenue of $174.35 million for the quarter, compared to analysts’ expectations of $174.40 million. NovoCure had a negative net margin of 20.79% and a negative return on equity of 38.82%. The company’s revenue for the quarter was up 8.2% compared to the same quarter last year. During the same quarter last year, the company earned ($0.61) EPS. On average, equities analysts expect that NovoCure Limited will post -1.3 EPS for the current fiscal year.

Hedge Funds Weigh In On NovoCure

A number of institutional investors and hedge funds have recently added to or reduced their stakes in NVCR. Morgan Stanley increased its holdings in shares of NovoCure by 453.4% during the fourth quarter. Morgan Stanley now owns 5,069,895 shares of the medical equipment provider’s stock valued at $65,554,000 after purchasing an additional 4,153,741 shares during the period. Soleus Capital Management L.P. grew its position in NovoCure by 25.0% in the 2nd quarter. Soleus Capital Management L.P. now owns 6,904,302 shares of the medical equipment provider’s stock valued at $122,897,000 after buying an additional 1,382,888 shares in the last quarter. Jacobs Levy Equity Management Inc. increased its stake in NovoCure by 1,093.2% during the 4th quarter. Jacobs Levy Equity Management Inc. now owns 1,223,755 shares of the medical equipment provider’s stock valued at $15,823,000 after buying an additional 1,121,192 shares during the period. American Century Companies Inc. raised its position in shares of NovoCure by 1,354.7% during the 2nd quarter. American Century Companies Inc. now owns 1,029,874 shares of the medical equipment provider’s stock worth $18,332,000 after buying an additional 959,079 shares in the last quarter. Finally, Healthcare of Ontario Pension Plan Trust Fund acquired a new stake in shares of NovoCure in the 4th quarter worth approximately $11,991,000. 84.61% of the stock is owned by institutional investors.

NovoCure Company Profile

NovoCure is a global oncology company pioneering Tumor Treating Fields (TTFields), a novel anti-mitotic therapy for solid tumors. The company’s non-invasive treatment platforms deliver low-intensity, alternating electric fields designed to disrupt cancer cell division. NovoCure’s approach offers an alternative modality to complement existing therapies in oncology, with a focus on hard-to-treat malignancies.

Founded in 2000 and headquartered in Haifa, Israel, NovoCure maintains a second operational center in Portsmouth, New Hampshire.